Zhejiang Jingsin Pharmaceutical Co., Ltd. Independent Director 2025 Annual Report
As an independent director of Zhejiang Jingsin Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), in accordance with the Company Law, the Corporate Governance Guidelines for Listed Companies, the Shenzhen Stock Exchange Main Board Listed Company Standardized Operation Guide No. 1, the Administrative Measures for Independent Directors of Listed Companies, and other relevant laws, regulations, and the Articles of Association and the Independent Director Work System, I have always faithfully, diligently, and independently performed my duties, actively attended relevant meetings of the Company in 2025, carefully reviewed all proposals of the Board of Directors, and fully exercised the role of an independent director to effectively protect the interests of the Company and all shareholders, especially small and medium shareholders. The following is my report on the performance of my duties in 2025:
I. Basic Information of Independent Director
Zhang Daliang, with a Master's degree, is currently the Deputy Director of the Innovation Research Center for Health Industry at Zhejiang University, Deputy Director of the Marketing Management Research Institute at Zhejiang University, and a professor at the School of Management, Zhejiang University. From October 2022 to October 2025, he served as an independent director of the Company.
During the reporting period, I conducted a self-assessment of my independence and believe that I do not have any circumstances that affect my independence, and I meet the independence requirements stipulated in Article 6 of the Administrative Measures for Independent Directors of Listed Companies.